

HYPOGONADOTROPIC HYPOGONADISM (KALLMANN)

PANEL DG 3.8.1 (58 GENES)

<i>Gene</i>	<i>Twist X2 covered >10x</i>	<i>Twist X2 covered >20x</i>	<i>WGS covered >10x</i>	<i>WGS covered >20x</i>	<i>Associated Phenotype description and OMIM disease ID</i>
ADCY3	100.0%	100.0%	100.0%	99.6%	{Obesity, susceptibility to, BMIQ19}, 617885
ANOS1	100.0%	99.8%	99.1%	73.9%	Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700
ARHGAP35	100.0%	100.0%	100.0%	99.4%	
AXL	100.0%	100.0%	100.0%	99.6%	
CCDC141	99.5%	98.9%	100.0%	99.1%	
CHD7	100.0%	100.0%	100.0%	99.5%	Hypogonadotropic hypogonadism 5 with or without anosmia, 612370;CHARGE syndrome, 214800
CNGA2	99.9%	99.7%	98.6%	72.1%	
CUL4B	100.0%	99.9%	98.1%	72.0%	Intellectual developmental disorder, X-linked syndromic, Cabezas type, 300354

DCAF17	100.0%	100.0%	100.0%	99.8%	Woodhouse-Sakati syndrome, 241080
DCC	100.0%	100.0%	100.0%	99.5%	Mirror movements 1 and/or agenesis of the corpus callosum, 157600;Esophageal carcinoma, somatic, 133239;Colorectal cancer, somatic, 114500;Gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542
DUSP6	100.0%	100.0%	100.0%	99.3%	Hypogonadotropic hypogonadism 19 with or without anosmia, 615269
FEZF1	100.0%	100.0%	100.0%	99.0%	Hypogonadotropic hypogonadism 22, with or without anosmia, 616030
FGF17	100.0%	100.0%	100.0%	99.9%	Hypogonadotropic hypogonadism 20 with or without anosmia, 615270
FGF8	100.0%	100.0%	100.0%	99.7%	Hypogonadotropic hypogonadism 6 with or without anosmia, 612702

FGFR1	100.0%	100.0%	100.0%	99.8%	Pfeiffer syndrome, 101600;Hypogonadotropic hypogonadism 2 with or without anosmia, 147950;Jackson-Weiss syndrome, 123150;Hartsfield syndrome, 615465;Trigonocephaly 1, 190440;Osteoglophonic dysplasia, 166250;Encephalocraniocutaneous lipomatosis, somatic mosaic, 613001
FLRT3	100.0%	99.7%	100.0%	99.9%	Hypogonadotropic hypogonadism 21 with anosmia, 615271
FSHB	98.7%	98.0%	100.0%	100.0%	Hypogonadotropic hypogonadism 24 without anosmia, 229070
GLI2	100.0%	100.0%	100.0%	99.9%	Culler-Jones syndrome, 615849;Holoprosencephaly 9, 610829
GNRH1	100.0%	100.0%	100.0%	97.9%	?Hypogonadotropic hypogonadism 12 with or without anosmia, 614841
GNRHR	100.0%	100.0%	100.0%	99.8%	Hypogonadotropic hypogonadism 7 without anosmia, 146110

HESX1	100.0%	100.0%	100.0%	97.4%	Pituitary hormone deficiency, combined, 5, 182230;Septo-optic dysplasia, 182230;Growth hormone deficiency with pituitary anomalies, 182230
HS6ST1	100.0%	100.0%	100.0%	99.6%	{Hypogonadotropic hypogonadism 15 with or without anosmia}, 614880
IGSF10	100.0%	100.0%	100.0%	99.6%	
IL17RD	100.0%	100.0%	100.0%	99.8%	Hypogonadotropic hypogonadism 18 with or without anosmia, 615267
KISS1	100.0%	100.0%	100.0%	95.9%	?Hypogonadotropic hypogonadism 13 with or without anosmia, 614842
KISS1R	100.0%	100.0%	100.0%	99.9%	Hypogonadotropic hypogonadism 8 with or without anosmia, 614837;?Precocious puberty, central, 1, 176400
KLB	100.0%	100.0%	100.0%	99.7%	
LEP	100.0%	100.0%	100.0%	99.4%	Obesity, morbid, due to leptin deficiency, 614962
LEPR	94.6%	94.6%	100.0%	99.3%	Obesity, morbid, due to leptin receptor deficiency, 614963
LHB	100.0%	100.0%	100.0%	100.0%	Hypogonadotropic hypogonadism 23 with or without anosmia, 228300

LHX3	100.0%	100.0%	100.0%	99.8%	Pituitary hormone deficiency, combined, 3, 221750
NDNF	100.0%	100.0%	100.0%	99.0%	Hypogonadotropic hypogonadism 25 with anosmia, 618841
NOS1	100.0%	100.0%	100.0%	99.6%	
NR0B1	100.0%	99.8%	99.7%	81.5%	Adrenal hypoplasia, congenital, 300200;46XY sex reversal 2, dosage-sensitive, 300018
NSMF	100.0%	100.0%	100.0%	99.9%	Hypogonadotropic hypogonadism 9 with or without anosmia, 614838
NTN1	100.0%	100.0%	100.0%	99.6%	Mirror movements 4, 618264
PCSK1	100.0%	100.0%	100.0%	99.5%	{Obesity, susceptibility to, BMIQ12}, 612362;Endocrinopathy due to proprotein convertase 1/3 deficiency, 600955
PHF6	100.0%	100.0%	98.9%	75.6%	Borjeson-Forssman-Lehmann syndrome, 301900
PLXNA1	100.0%	100.0%	100.0%	100.0%	Dworschak-Punetha neurodevelopmental syndrome, 619955

PNPLA6	100.0%	100.0%	100.0%	99.9%	Spastic paraplegia 39, autosomal recessive, 612020;Oliver-McFarlane syndrome, 275400;?Laurence-Moon syndrome, 245800;Boucher-Neuhauser syndrome, 215470
POLG	100.0%	100.0%	100.0%	99.8%	Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459;Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662;Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700;Progressive external ophthalmoplegia, autosomal dominant 1, 157640;Progressive external ophthalmoplegia, autosomal recessive 1, 258450
POLR3A	100.0%	100.0%	100.0%	99.5%	Wiedemann-Rautenstrauch syndrome, 264090;Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694

POLR3B	100.0%	99.9%	100.0%	99.0%	Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381;Charcot-Marie-Tooth disease, demyelinating, type 1I, 619742
POLR3GL	100.0%	100.0%	100.0%	99.7%	Short stature, oligodontia, dysmorphic facies, and motor delay, 619234
PROK2	100.0%	100.0%	100.0%	99.7%	Hypogonadotropic hypogonadism 4 with or without anosmia, 610628
PROKR2	100.0%	100.0%	100.0%	99.8%	Hypogonadotropic hypogonadism 3 with or without anosmia, 244200
PROP1	100.0%	100.0%	99.9%	96.7%	Pituitary hormone deficiency, combined, 2, 262600
SEMA3A	100.0%	100.0%	100.0%	99.7%	{Hypogonadotropic hypogonadism 16 with or without anosmia}, 614897
SEMA3E	100.0%	100.0%	100.0%	99.7%	
SOX10	100.0%	100.0%	100.0%	99.9%	Waardenburg syndrome, type 4C, 613266;PCWH syndrome, 609136;Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584

SOX11	100.0%	100.0%	100.0%	98.5%	Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism, 615866
SOX2	100.0%	100.0%	100.0%	99.4%	Optic nerve hypoplasia and abnormalities of the central nervous system, 206900;Microphthalmia, syndromic 3, 206900
SPRY4	100.0%	100.0%	100.0%	99.8%	Hypogonadotropic hypogonadism 17 with or without anosmia, 615266
TAC3	100.0%	100.0%	100.0%	99.9%	Hypogonadotropic hypogonadism 10 with or without anosmia, 614839
TACR3	100.0%	99.8%	100.0%	99.3%	Hypogonadotropic hypogonadism 11 with or without anosmia, 614840
TCF12	100.0%	100.0%	100.0%	99.6%	Craniosynostosis 3, 615314;Hypogonadotropic hypogonadism 26 with or without anosmia, 619718
TENM1	99.9%	99.5%	98.8%	75.0%	
WDR11	100.0%	100.0%	100.0%	99.6%	Intellectual developmental disorder, autosomal recessive 78, 620237;Hypogonadotropic hypogonadism 14 with or without anosmia, 614858

TWIST X2 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry.

TWIST X2 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry.

srWGS GRCh38 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.

srWGS GRCh38 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : March 17th, 2023.

This list is accurate for panel version DG 3.8.1

[EAS.GenProductCoverage.pdf.footer.ad01](#)